Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.
König D, Schär S, Vuong D, Guckenberger M, Furrer K, Opitz I, Weder W, Rothschild SI, Ochsenbein A, Zippelius A, Addeo A, Mark M, Eboulet EI, Hayoz S, Thierstein S, Betticher DC, Ris HB, Stupp R, Curioni-Fontecedro A, Peters S, Pless M, Früh M.
König D, et al. Among authors: betticher dc.
ESMO Open. 2022 Apr;7(2):100455. doi: 10.1016/j.esmoop.2022.100455. Epub 2022 Apr 7.
ESMO Open. 2022.
PMID: 35398718
Free PMC article.